Recombinant HSV-1 γ134.5 Segmentation for Cancer-Selective Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic herpes simplex viruses (HSV) with γ1 34.5 gene deletion face challenges in replicating effectively within cancer cells and activating systemic antitumor responses due to host defenses, leading to incomplete tumor eradication and potential re-growth of cancer cells.
Innovation Solution
A recombinant HSV-1 expressing only the C-terminal portion of the γ1 34.5 protein, combined with deletions or replacements of non-essential genes, enhances viral replication and immune activation in cancer cells while resisting interferon-mediated clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the γ1 34.5 gene is deleted to reduce virulence and enhance antitumor activity, then the virus becomes less harmful to normal tissues, but the virus replication efficiency in cancer cells is reduced due to host PKR activation
Solution Approach 1:
The γ1 34.5 gene is segmented into two functional domains: the N-terminal domain (amino acids 1-146) which mediates harmful effects on normal tissues, and the C-terminal domain (amino acids 147-263) which is required for viral replication. The invention deletes only the N-terminal domain while retaining the C-terminal domain, thereby separating the harmful functions from the beneficial replication functions.
Solution Approach 2:
The invention applies local quality modification by specifically targeting the N-terminal domain of γ1 34.5 for deletion. This domain is responsible for the virus's harmful effects on normal tissues, while the C-terminal domain retains the essential replication function. By modifying only the local N-terminal region rather than the entire gene, the virus achieves reduced virulence while maintaining productivity.
2Reliability
If the γ1 34.5 gene is deleted to activate immune responses, then antitumor immunity is enhanced, but the virus is cleared more rapidly by interferon-mediated immune defenses
Solution Approach 1:
The γ1 34.5 gene is segmented into two functional domains: the N-terminal domain (amino acids 1-146) which mediates harmful effects on normal tissues, and the C-terminal domain (amino acids 147-263) which is required for viral replication. The invention deletes only the N-terminal domain while retaining the C-terminal domain, thereby separating the harmful functions from the beneficial replication functions.
Solution Approach 2:
The invention applies local quality modification by specifically targeting the N-terminal domain of γ1 34.5 for deletion. This domain is responsible for the virus's harmful effects on normal tissues, while the C-terminal domain retains the essential replication function. By modifying only the local N-terminal region rather than the entire gene, the virus achieves reduced virulence while maintaining productivity.
3Adaptability or versatility
If non-essential genes are deleted or replaced to reduce viral complexity, then the virus becomes more targeted to cancer cells, but the overall viral fitness and replication capacity are reduced
Solution Approach 1:
The γ1 34.5 gene is segmented into two functional domains: the N-terminal domain (amino acids 1-146) which mediates harmful effects on normal tissues, and the C-terminal domain (amino acids 147-263) which is required for viral replication. The invention deletes only the N-terminal domain while retaining the C-terminal domain, thereby separating the harmful functions from the beneficial replication functions.
Solution Approach 2:
The invention applies local quality modification by specifically targeting the N-terminal domain of γ1 34.5 for deletion. This domain is responsible for the virus's harmful effects on normal tissues, while the C-terminal domain retains the essential replication function. By modifying only the local N-terminal region rather than the entire gene, the virus achieves reduced virulence while maintaining productivity.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
A method for treating a subject with cancer by administering to the subject a therapeutically effective amount of a recombinant Herpes Simplex Virus-1 (HSV-1) that expresses only a C-terminal portion of γ134.5 protein (e.g., amino acid residues 147-263) with no wild-type or intact γ134.5 protein expression is provided. The recombinant HSV-1 of this invention instigates immune activation, selectively replicates in cancer cells, and resists clearance by interferon.